$WAT

JPMorgan Adjusts Price Target on Waters to $435 From $400

JPMorgan raised its price target for Waters Corporation to $435 from $400. The company recently launched Waters AI Link, a new product. Waters' stock is currently trading at $429.17, with a 5-day change of -0.68% and a year-to-date change of +12.99%.

Original reporting
Published Oct 14, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$WAT
Bullish
high confidence
Mentioned
$WAT
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$WATBullishMed
01

Why it matters

The analyst upgrade may trigger buying interest and modest price appreciation.

02

Market read

Analyst target changes are a common catalyst for short‑term moves; this upgrade signals a positive outlook for WAT.

03

What to watch

Potential regulatory or supply‑chain risks not addressed in the target change.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Waters Corp. (WAT) is a leading provider of analytical instruments for labs and industrial markets.

Company-level read

Ticker impact

$WATBullishHigh confidence
Context

JPMorgan raised its price target for Waters Corp. to $435 from $400, a new analyst recommendation.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Analyst target upgrades are fresh, material information that can move the stock in the short term.

Market effects

May lift peer water‑treatment stocks as sector sentiment improves.

Primarily U.S. market impact; limited regional effect.

Limited to investors tracking water‑treatment sector.

Counterpoint

Target raise could be premature if recent earnings miss expectations.

Key entities

  • JPMorgan

    Investment bank that issued the new price target.

  • Waters Corp.

    Subject of the price‑target adjustment.

Related articles

$BRKRHighAI 8/10

Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.

$WATHighAI 8/10

Is Wall Street Bullish or Bearish on Waters Corporation Stock?

Waters Corporation (WAT), a $40.7B life sciences and diagnostics company, reported Q2 2026 adjusted EPS of $3.05 and revenue of $1.65B, exceeding expectations. The stock has risen 43% over 52 weeks, outperforming the S&P 500. Analysts expect 10.9% EPS growth for 2026, with a consensus 'Moderate Buy' rating and a mean price target of $438.43.

$WATMed

WAT Upgraded by Piper Sandler -- Price Target Raised to $480

Piper Sandler upgraded Waters Corporation (WAT) to Overweight, raising its price target to $480 from $400. The company's stock is currently trading at $423.22, slightly above its GF Value™ of $411.65, indicating a 2.8% overvaluation. Waters Corporation has a GF Score™ of 95/100, reflecting strong growth and momentum but moderate financial strength. Insider activity shows recent selling of $1,442,930 worth of shares.

$WATHighAI 9/10

Waters (WAT) Q2 2026 Earnings Call Transcript

Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.

$WATMedAI 8/10

Waters Q2 Earnings Call Highlights

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.